AbbVie

Open: 147.02 Close: 146.69 Change: -0.33

We programmed an AI to read Internet. This is what it found out about AbbVie Stock.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, ABBV, company, equal, opportunity, employer, include, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie trades on the NYSE under the ticker symbol ABBV. The company trades on NYSE. If you had invested in Abbvie stock at $35.12 in 2013, your return over the last 10 years would be 317.68%.

Today's News

AbbVie Inc. (ABBV) stock price today, quote & news | seeking alpha. Join now Search for Symbols, analysts, keywords Log in ABBV to see this view ratings - Rating: Not Covered. AbbVie is an equal opportunity employer including disability/vets. Senior Scientist I, Purification at ABBVIE is a senior scientist at the company. Electro-Mechanical Industrialization Lead at abbvie.com. Electro-mechanical industrialization lead at abvie. AbbVie is an equal opportunity employer. AbbVie is an equal opportunity employer including disability/vets. Corvadis is already underway in its mission, having contracted with Sandoz to commercialise and market Hyrimoz (adalimumab-adaz) – a biosimilar for Abbvies blockbuster Humira. Enzyme Replacement Therapy Market report from Global Insight Services is the single authoritative source of intelligence on Enzyme replacement Therapy Market. AbbVie ABBV, Novo Nordisk NVO and Eli Lilly LLY – have been notably hot, all outperforming the S&P 500 handily during the period. AbbVies ARCH platform is one of the 2023 Bio-IT World Innovative Practices winners. The ARCH is a harmonized corpus that is over 124TB in size. CVS Health Corp launches new company called Cordavis that will work directly with manufacturers to commercialize and co-produce biosimilar medicines for the U.S. The company next year will partner with Swiss drugmaker Novartis (NOVN.S) Sandoz unit. AbbVie is recruiting an NPI Project Manager to join our diverse team in Abbvie North Dublin. The role requires problem-solving, attention to detail, results orientation, creativity, and strong communication skills. Associate Director, Clinical Development - Aesthetics is seeking a highly motivated and innovative candidate who will contribute to multi-disciplinary collaborative environment. US Credentialing is an essential requirement of your position. It is AbbVies policy to employ qualified persons of the greatest ability without discrimination against any employee or applicant for employment because of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information, gender identity or expression. Abbvie trades on the NYSE under the ticker symbol ABBV. The companys market cap is $258.91B. If you had invested in AbbVie stock at $35.12 in 2013, your return over the last 10 years would be 317.68%. European Commission recently approved AbbVies atogepant (Aquipta) for the prophylaxis of migraine in adults who have 4 or more migraine days per month. European Commission approval of AQUIPTA is a significant milestone for people suffering from four or more migraines.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, ABBV, company, equal, opportunity, employer, include, and the most common words in the summary are: abbvie, stock, job, market, price, abbv, news, . One of the sentences in the summary was: If you had invested in Abbvie stock at $35.12 in 2013, your return over the last 10 years would be 317.68%.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #job #market #price #abbv #news.